エピソード

  • Principles of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma: Patient Selection Strategies

    Principles of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma: Patient Selection Strategies
    2022/06/09

    Large B-cell lymphomas (LBCLs) are one of the most common subtypes of non-Hodgkin lymphomas and while 1st-line standard of care has remained unchanged, the treatment paradigm has undergone a shift in recent years due to the development of novel therapeutic agents. These novel therapies include monoclonal antibody (mAb) therapies, mAb-conjugates, and chimeric antigen receptor (CAR)-T cell therapies.
    続きを読む 一部表示
    8 分
  • Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies

    Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies
    2022/06/09

    Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies
    続きを読む 一部表示
    37 分
  • Disease Burden and Overview of Large B-Cell Lymphomas

    Disease Burden and Overview of Large B-Cell Lymphomas
    2022/06/09

    B-cell lymphomas consist of a heterogenous group of lymphoproliferative neoplasms originating from B-lymphocytes.  
    続きを読む 一部表示
    4 分
  • Management of Adverse Effects Associated With Novel Therapies

    Management of Adverse Effects Associated With Novel Therapies
    2022/06/09

    Management of relapsed/refractory LBCLs remains a substantial and persistent clinical challenge, including optimal treatment sequencing, therapy evaluation and patient selection, and toxicity management.
    続きを読む 一部表示
    13 分